There is a crescendo of policies and programs for healthcare interoperability and electronic prior authorization, but it is a complicated proposition, says Kim Boyd at AMCP Nexus 2022.
No one seems to disagree that data ought to flow more freely through the U.S. healthcare system and that processes like prior authorization should happen faster and be more automated
But in a session today at the AMCP Nexus 2022 meeting, Kim Boyd sketched a complex picture development of technology standards and statutory and regulatory history.
“The path to interoperability and specifically to PA (prior authorization) improvement and automation, data and cost transparency is one that has lots of curves, speedbumps— and a lot of roadblocks,” said Boyd, who is senior consultant, regulatory resource center lead for Point-of-Care Partners, a healthcare IT management consulting company in Hollywood, Florida.
But Boyd also spoke about a “crescendo of polices and standards” to improve interoperability — the ability of different healthcare IT systems and devices to communicate with each other — and patient empowerment.
Boyd traced the legislative and regulatory history of interoperability and electronic prior authorization back to the 21st Century Cures Act. Federal action went into something of a lull during the height of the COVID-19 pandemic, Boyd said, so many states have stepped in with laws or rules concerning data-sharing.
Boyd also described the prominent role of the standards development organizations,such Health Level 7, which developed the Fast Healthcare Interoperability Resources (FHIR) standard — referred to almost exclusively by its acronym, FHIR (pronounced fire). She also mentioned the National Council for Prescription Drug Programs and X12.
Boyd noted the growing role of specialty medication in healthcare and the difficulties it poses for streamlining and automation.
“Specialty pharmacy today has no clear or consistent entry point to automation,” Boyd said. “The current state of specialty prescribing drives us to use portals, web searches, cheat sheets and binders.”
Will Keytruda and Opdivo Finally Get Some Price Competition? | AMCP Nexus 2022October 14th 2022
EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.
Trikafta Effective But Costly, Says Prime Therapeutics | AMCP Nexus 2022October 14th 2022
A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022October 13th 2022
Express Scripts' Aimee Tharaldson discussed the growing number of gene therapies in her keynote talk today on specialty drug at AMCP Nexus 2022. She listed 12 approved gene therapies, eight in the near-term pipeline for hemophilia and another seven for other diseases that may be approved next year.
Accumulators, Maximizers Exacerbate Healthcare Disparities, Says Janssen Research | AMCP Nexus 2022October 13th 2022
Research by Janssen shows that non-White patients are disproportionately affected by the accumulators and maximizers that PBMs use to blunt the financial consequences of copay assistance cards.
2 Clarke Drive
Cranbury, NJ 08512